Human hydroxysteroid dehydrogenases and pre-receptor regulation: Insights into inhibitor design and evaluation

Journal of Steroid Biochemistry and Molecular Biology

Volumn 125, Issue 1-2, 2011, Pages 46-56

  Penning, Trevor M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 130C John Morgan Bldg ^*  (United States)

Author keywords

Aldo keto reductases; Selective steroid receptor modulator; Short chain dehydrogenase reductases; Steroid hormone receptors

Indexed keywords

3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; ENZYME INHIBITOR; HYDROXYSTEROID DEHYDROGENASE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PF 915275;

CATALYSIS; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; KINETICS; NONHUMAN; OXIDATION; REDUCTION; REVIEW; STEREOCHEMISTRY; THERMODYNAMICS; VALIDATION PROCESS;

DRUG DESIGN; HUMANS; HYDROXYSTEROID DEHYDROGENASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; RECEPTORS, STEROID; STEROIDS; THERMODYNAMICS;

EID: 79957676307     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2011.01.009     Document Type: Review

References (112)

1. T.M. Penning Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action Hum. Reprod. Update 9 2003 193 205 (Pubitemid 36827058)
2. D.R. Bauman, S. Steckelbroeck, and T.M. Penning The roles of aldo-keto reductases in steroid hormone action Drugs News Perspect. 17 2004 563 578 (Pubitemid 40136607)
3. H. Jornvall, B. Persson, M. Krook, S. Atrian, R. Gonzalez-Duarte, J. Jeffery, and D. Ghosh Short-chain dehydrogenases/reductases (SDR) Biochemistry 34 1995 6003 6013
4. D.R. Bauman, S. Steckelbroeck, M.V. Williams, D.M. Peehl, and T.M. Penning Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human prostate that converts 5α-androstane-3α, 17β-diol to 5α-dihydrotestosterone: a potential therapeutic target for androgen dependent disease Mol. Endocrinol. 20 2006 444 458 (Pubitemid 43152517)
5. T. Rizner, H.-K. Lin, D.M. Peehl, S. Steckelbroeck, D.R. Bauman, and T.M. Penning Human type 3 3α-hydroxysteroid dehydrogenase (AKR1C2) and androgen metabolism in prostate cells Endocrinology 144 2003 2922 2932 (Pubitemid 36819895)
6. J.W. Funder, P.T. Pearce, R. Smith, and A.I. Smith Mineralocorticoid action: target tissue specificity is enzyme not receptor, mediated Science 242 4878 1988 583 585 (Pubitemid 18263202)
7. J.R. Seckl, and B.R. Walker Minireview: 11β-hydroxysteroid dehydrogenase type 1 a tissue-specific amplifier of glucocorticoid action Endocrinology 142 2001 1371 1376 (Pubitemid 32299662)
8. P.M. Stewart, and C.B. Whorwood 11β-Hydroxysteroid dehydrogenase activity and corticosteroid hormone action Steroids 59 2 1994 90 95 (Pubitemid 24080364)
9. J. Adamski, T. Normand, F. Leenders, D. Monte, A. Begue, S. Stehelin, P.W. Jungblut, and Y. de Launoit Molecular cloning of a novel widely expressed human 80 kDa 17β-hydroxysteroid dehydrogenase IV Biochem. J. 311 Pt 2 1995 437 443
10. S. Andersson 17β-hydroxysteroid dehydrogenase: isozymes and mutations J. Endocrinol. 146 1995 197 200
11. F. Labrie, V. Luu-The, S.X. Lin, J. Simard, C. Labrie, M. El-Alfy, G. Pelletier, and A. Belanger Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease J. Mol. Endocrinol. 25 2000 1 16 (Pubitemid 30618058)
12. K.-M. Fung, E.H. Shea-Samara, C. Wong, R. Krin, A.M. Jones, B. Bane, C.Z. Liu, J.T. Yang, J.V. Pitha, D.J. Culkin, B.P. Koop, T.M. Penning, and H.-K. Lin Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with the androgen receptor in prostate carcinoma Endocr. Related Cancer 13 2006 169 180
13. T.M. Penning, M.E. Burczynski, J.M. Jez, H.-K. Lin, H. Ma, M. Moore, K. Ratnam, and N. Palackal Structure-function aspects and inhibitor design of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) Mol. Cell. Endcorinol. 171 2001 137 149 (Pubitemid 32098208)
14. M.L. Casey, P.C. MacDonald, and S. Andersson 17β-Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium J. Clin. Invest. 94 5 1994 2135 2141
15. T.M. Penning, M.E. Burczynski, J.M. Jez, C.-F. Hung, H.-K. Lin, H. Ma, M. Moore, N. Palackal, and K. Ratnam Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones Biochem. J. 351 2000 67 77
16. N. Ibrahim, and G. Hortobagyi The evolving role of specific estrogen receptor modulators (SERMs) Surg. Oncol. 8 1999 103 122
17. D. McDonnell Selective estrogen receptor modulators (SERMs): a first step in the development of a perfect hormone replacement therapy regimen J. Soc. Gynecol. 7 2000 S10 15
18. F. Labrie, A. Belanger, and J. Simard Intracrinology autonomy and freedom of peripheral tissues Annu. Endocrinol. 56 1995 23 29
19. F. Cadepond, A. Ulmann, and E.E. Baulieu RU486 (mifepristone): mechanisms of action and clinical uses Annu. Rev. Med. 48 1997 129 156 (Pubitemid 27101820)
20. M.J. Crooij, C.C. de Nooyer, B.R. Rao, G.T. Berends, L.J. Gooren, and J. Janssens Termination of early pregnancy by the 3β-hydroxysteroid dehydrogenase inhibitor epostane N. Engl. J. Med. 319 13 1988 813 817
21. M.C. Byrns, Y. Jin, and T.M. Penning Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights J. Steroid Biochem. Mol. Biol. 125 2011 95 104
22. O. El-Kabbani, U. Dhagat, and A. Hara Inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1) J. Steroid Biochem. Mol. Biol. 125 2011 105 111
23. D.V. Kratschmar, A. Vuorinen, T.A. Cunha, G. Wolber, D. Classen-Houben, O. Doblhoff, D. Schuster, and A. Odermatt Characterization of activity and binding mode of glycyrrhetinic acid derivatives inhibiting 11β- hydroxysteroid dehydrogenase type 2 J. Steroid Biochem. Mol. Biol. 125 2011 129 142
24. S. Marchais-Oberwinkler, C. Henn, G. Möller, T. Klein, M. Negri, A. Oster, A. Spadaro, R. Werth, M. Wetzel, K. Xu, M. Frotscher, R.W. Hartmann, and J. Adamski 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development J. Steroid Biochem. Mol. Biol. 125 2011 66 82
25. D. Poirier Contribution to the development of inhibitors of 17β hydroxysteroid dehydrogenase types 1 and 7: key tools for studying and treating estrogen-dependent diseases J. Steroid Biochem. Mol. Biol. 125 2011 83 94
26. D. Schuster, D. Kowalik, J. Kirchmair, C. Laggner, P. Markt, C. Aebischer-Gumy, F. Ströhle, G. Möller, G. Wolber, T. Wilckens, A. Langer, J. Odermatt, and Adamski Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening J. Steroid Biochem. Mol. Biol. 125 2011 148 161
27. J.L. Thomas, K.M. Bucholtz, and B. Kacsoh Selective inhibition of human 3β-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer J. Steroid Biochem. Mol. Biol. 125 2011 57 65
28. J.M. Jez, M.J. Bennett, B.P. Schlegel, M. Lewis, and T.M. Penning Comparative anatomy of the aldo-keto reductase superfamily Biochem. J. 325 1997 625 636 (Pubitemid 27438032)
29. Y. Jin, and T. Penning Multiple steps determine the overall rate of the reduction of 5α-dihydrotestosterone catalyzed by human type 3 3α-hydroxysteroid dehydrogenase: implications for the elimination of androgens Biochemistry 2006 13054 13063 (Pubitemid 44763428)
30. F. Labrie, V. Luu-The, S.-X. Lin, C. Labrie, J. Simard, R. Breton, and A. Belanger The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology Steroids 62 1997 148 158 (Pubitemid 27066999)
31. 4 isomerase (3β-HSD) gene: adrenal and gonadal specificity DNA Cell Biol. 10 1991 701 711
32. 4 isomerase by site-directed mutagenesis and expression in HeLa cells J. Biol. Chem. 266 23 1991 14842 14845 (Pubitemid 21907580)
33. L.J. Askonas, J.W. Ricigliano, and T.M. Penning The kinetic mechanism catalysed by homogeneous rat liver 3α-hydroxysteroid dehydrogenase. Evidence for binary and ternary dead-end complexes containing non-steroidal anti-inflammatory drugs Biochem. J. 278 3 1991 835 841
34. W.C. Cooper, Y. Jin, and T.M. Penning Elucidation of a complete kinetic mechanisms for a mammalian hydroxysteroid dehydrogenase (HSD) and identification of all enzyme forms on the reaction coordinate: the example of rat liver 3α-HSD (AKR1C9) J. Biol. Chem. 282 2007 33484 33493 (Pubitemid 350159515)
35. K. Ratnam, H. Ma, and T.M. Penning The arginine 276 anchor for NADP(H) dictates fluorescence kinetic transients in 3α-hydroxysteroid dehydrogenase, a representative aldo-keto reductase Biochemistry 38 1999 7856 7864
36. T.L Rizner, J. Adamski, and J. Stojan 17β-Hydroxysteroid dehydrogenase from Cocliobolus lunatus: model structure and substrate specificity Arch. Biochem. Biophys. 384 2000 255 262 (Pubitemid 32012799)
37. S. Ueda, M. Oda, S. Imamura, and M. Ohnishi Transient-phase kinetic studies on the nucleotide binding to 3α-hydroxystreoid dehydrogenase from Pseudomonas sp. B-831 using fluorescence stopped-flow procedures Eur. J. Biochem. 271 2004 1774 1780 (Pubitemid 38586309)
38. A. Castro, J. Zhu, G. Alton, P. Rejto, and J. Emolieff Assay optimization and kinetic profile of the human and the rabbit isoforms of 11β-HSD1 Biochem. Biophys. Res. Commun. 357 2007 561 566 (Pubitemid 46603167)
39. J. Warren, and R. Crist Site-specificity and mechanism of human placental 17β-hydroxysteroid dehydrogenase Arch. Biochem. Biophys. 118 1967 577 584
40. 50) of an enzymatic reaction Biochem. Pharmacol. 22 23 1973 3099 3108
41. M.G. Biswas, and D.W. Russell Expression cloning and characterization of oxidative 17β- and 3α-hydroxysteroid dehydrogenases from rat and human prostate J. Biol. Chem. 272 25 1997 15959 15966 (Pubitemid 27265577)
42. S. Steckelbroeck, Y. Jin, S. Gopishetty, B. Oyesanmi, and T.M. Penning Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action J. Biol. Chem. 279 11 2004 10784 10795 (Pubitemid 38379543)
43. H.F. Fisher, E.E. Conn, B. Vennesland, and F.H. Westheimer The enzymatic transfer of hydrogen. I. The reaction catalyzed by alcohol dehydrogenase J. Biol. Chem. 202 2 1953 687 697
44. F.A. Loewus, P. Ofner, H.F. Fisher, F.H. Westheimer, and B. Vennesland The enzymatic transfer of hydrogen. II. The reaction catalyzed by lactic dehydrogenase J. Biol. Chem. 202 2 1953 699 704
45. W.H. Kersey, and R.B. Wilcox Stereochemistry of hydrogen transfer by rat ovary 20α-hydroxysteroid dehydrogenase Biochemistry 9 5 1970 1284 1286
46. K.M. Bohren, C.E. Girmshaw, C.-J. Lai, D. Harrison, D. Ringe, G.A. Petsko, and K.H. Gabbay Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme Biochemistry 33 1994 2021 2032 (Pubitemid 24099596)
47. C.E. Grimshaw, K.M. Bohren, C.J. Lai, and K.H. Gabbay Human aldose reductase: pK of tyrosine 48 reveals the preferred ionization state for catalysis and inhibition Biochemistry 34 44 1995 14374 14384
48. B.P. Schlegel, J.M. Jez, and T.M. Penning Mutagenesis of 3α-hydroxysteroid dehydrogenase reveals a "push-pull" mechanism for proton transfer in aldo-keto reductases Biochemistry 37 1998 3538 3548 (Pubitemid 28125582)
49. E. Vogan, C. Belamacina, X. He, H.W. Liu, D. Ringe, and G. Petsko Crystal structure of 1.8 A resolution of CDP-D-glucose 4, 6-dehydratase from Yersinia pseudotuberculosis Biochemistry 43 2004 3057 3067 (Pubitemid 38352256)
50. D. Ghosh, C.M. Weeks, P. Grochulski, W.L. Duax, M. Erman, R.L. Rimsay, and J.C. Orr Three-dimensional structure of holo 3α 20β- hydroxysteroid dehydrogenase: a member of a short-chain dehydrogenase family Proc. Natl. Acad. Sci. U. S. A. 88 1991 10064 10068 (Pubitemid 21915776)
51. D. Ghosh, Z. Wawrzak, C.M. Weeks, W.L. Duax, and M. Erman The refined three-dimensional structure of 3α 20β-hydroxysteroid dehydrogenase and possible roles of the residues conserved in short-chain dehydrogenases Structure 2 1994 629 640
52. D. Ghosh, V.Z. Pletnev, D.W. Zhu, Z. Wawrzak, W.L. Duax, W. Pangborn, F. Labrie, and S.X. Lin Structure of human estrogenic 17β-hydroxysteroid dehydrogenase at 2.20 A resolution Structure 3 5 1995 503 513
53. + Biochemistry 35 1996 10702 10711 (Pubitemid 26279649)
54. C. Filling, K.D. Berndt, J. Benach, S. Knapp, T. Prozoorovski, E. Nordling, R. Ladenstein, H. Jornvall, and U. Oppermann Critical residues for structure and catalysis in short-chain dehydrogenases/reductases J. Biol. Chem. 277 2002 25677 25684 (Pubitemid 34959957)
55. M. Negri, M. Recanatini, and R.W. Hartmann Insights in 17β-HSD1 enzyme kinetics and ligand binding by dynamic motion investigation PLoS One 5 8 2010 e12026
56. M. Akhtar, D.C. Wilton, I.A. Watkinson, and A.D. Rahimtula Substrate activation in pyridine nucleotide-linked reactions: illustrations from the steroid field Proc. R. Soc. Lond. B: Biol. Sci. 180 59 1972 167 177
57. D.R. Bauman, S. Rudnick, L. Szewczuk, G. Sridhar, and T.M. Penning Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes Mol. Pharmacol. 67 2005 60 68 (Pubitemid 40069966)
58. M.C. Byrns, S. Steckelbroeck, and T.M. Penning An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies Biochem. Pharmacol. 75 2 2008 484 493 (Pubitemid 350298472)
59. O El-Kabbani, P.J. Scammells, J. Gosling, U. Dhagat, S. Endo, T. Mastunnaga, M. Soda, and A. Hara Structure-guided design, synthesis, and evaluation of salicyclic acid-based inhibitors targeting a selectivity pocket in the active site of human 20α-hydroxystreoid dehydrogenase J. Med. Chem. 52 2009 3259 3264
60. D. Ghosh, M. Erman, Z. Wawrzak, W.L. Duax, and W. Pangborn Mechanism of inhibition of 3α 20β-hydroxysteroid dehydrogenase by a licorice-derived steroidal inhibitor Structure 2 10 1994 973 980
61. +-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins Proc. Natl. Acad. Sci. U. S. A. 80 1983 4504 4508 (Pubitemid 13077867)
62. T.M. Penning, I. Mukharji, S. Barrows, and P. Talalay Purification and properties of a 3α-hydroxysteroid dehydrogenase of rat liver cytosol and its inhibition by anti-inflammatory drugs Biochem. J. 222 3 1984 601 611 (Pubitemid 14007827)
63. P. Talalay Hydroxysteroid dehydrogenases P.D. Boyer, M. Lardy, K. Myrback, Enzymes 1963 NY Acad Press New York 177 202
64. A.K. Agarwal, and R.J. Auchus Minireview: cellular redox state regulates hydroxysteroid dehydrogenase activity and intracellular hormone potency Endocrinology 146 6 2005 2531 2538 (Pubitemid 40703963)
65. M. Papari-Zareei, A. Brandmaier, and R.J. Auchus Arginine 276 controls the directional preference of AKR1C9 (rat liver 3α-hydroxysteroid dehydrogenase) in human embryonic kidney 293 cells Endocrinology 147 4 2006 1591 1597
66. J.M. Day, P.A. Foster, H.J. Tutill, M.F. Parsons, S.P. Newman, S.K. Chander, G.M. Allan, H.R. Lawrence, N. Vicker, B.V. Potter, M.J. Reed, and A. Purohit 17β-Hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer Int. J. Cancer 122 9 2008 1931 1940 (Pubitemid 351441181)
67. P Velia, N. Davies, P. Rocha, H. Schrewe, J. Ride, and C. Bunce Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers Mol. Cancer 8 2009 121
68. L.L. Gathercole, and P.M. Stewart Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes J. Steroid Biochem. Mol. Biol. 122 2010 21 27
69. R. Ge, Y. Huang, G. Liang, and X. Li 11β-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development Curr. Med. Chem. 412-422 2010
70. J.M. Day, H.T. Tutill, A. Purohit, and M.J. Reed Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer and endometriosis Endocrine-Related Cancer 15 2008 665 692
71. D. Poirier 17β-Hydroxysteroid dehydrogenase inhibitors: a patent review Exp. Opin. Ther. Pat. 20 2010 1123 1145
72. T.M. Penning, J.W. Ricigliano, Nonsteroidal and nonprostanoid inhibitors of steroid and prostaglandin transforming enzymes, U.S. Patent 5,258,296 (Nov. 2nd) (1993).
73. S. Endo, T. Matsunaga, M. Soda, K. Tajima, H. Zhao, O. El-Kabbani, and A. Hara Selective inhibition of the tumor marker AKR1B10 by anti-inflammatory N-phenylanthraniic acids and glycyrrhetic acid Biol. Pharm. Bull. 33 2010 886 890
74. A.O. Adeniji, B.M. Twenter, M.C. Byrns, Y. Jin, J.D. Winkler, T.M. Penning, Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3), Bioorg. Med. Chem. Lett., in press.
75. U. Dhagat, S. Endo, R. Sumi, A. Hara, and O. El-Kabbani Selectivity determinants of inhibitor binding to human 20α-hydroxysteroid dehydrogenase: Crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3 5-dichlorosalicylic acid J. Med. Chem. 51 2008 4844 4848
76. U. Shah, C.D. Boyle, S. Chackalamannil, H. Baker, T. Kowalski, J. Lee, G. Terracina, and L. Zhang Azabicyclic sulfonamides as potent 11β-HSD1 inhibitors Bioorg. Med. Chem. Lett. 20 2010 1551 1554
77. Y. Zhu, S. Olson, A. Hermanowski-Vostak, S. Mundt, K. Shah, M. Springer, R. Thieringer, S. Wright, J. Xioa, H. Zokian, and J.M. Balkovec 4-Methyl-5-phenyl trizaoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 Bioorg. Med. Chem. Lett. 18 2008 3405 3411 (Pubitemid 351718310)
78. D. Roche, D. Carniato, C. Leriche, F. Lepifre, S. Christmann-Franck, U. Graedler, C. Charon, S. Bozec, L. Doare, F. Schmidlin, M. Lecomte, and E. Valuer Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 Bioorg. Med. Chem. Lett. 19 2009 2674 2678
79. M. Siu, T.O. Johnson, Y. Wang, S.K. Nair, W.D. Taylor, S.J. Cripps, J.J. Matthews, M.P. Edwards, T.A. Pauly, J. Ermolieff, A. Castro, N.A. Hosea, A. LaPaglia, A.N. Fanjul, and J.E. Vogel N-(pyridin-2-yl)aryl sulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: discovery of PF-915275 Bioorg. Med. Chem. Lett. 19 2009 3493 3497
80. X. Zhang, Y. Zhu-ou, L.-i. Du, J.-h. Chen, Y. Leng, and J.-h. Chen Derivatives of (phenylsulfonoamido-methyl)nicotine and (phenylsulfonomido- methyl)thiazole as novel 11β-hydroxysteroid dehydrogenase type 1 inhibitors: synthesis and biological activities in vitro Acta Pharmacol. Sin. 30 2009 1344 1350
81. D.L. McMinn, Y. Rew, A. Sudom, S. Caille, M. DeGraffenreid, X. He, R. Hungate, B. Jiang, J. Jaen, L.D. Julian, J. Kaizerman, P. Novak, D. Sun, H. Tu, S. Ursu, N. Walker, X. Yan, Q. Ye, Z. Wang, and J.P. Powers Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors Bioorg. Med. Chem. Lett. 19 2009 1446 1450
82. Y. Rew, D.L. McMinn, Z. Wang, X. He, R.W. Hungate, J.C. Jaen, A. Sudom, D. Sun, H. Tu, S. Ursu, E. Villemure, N.P.C. Walker, X. Yan, Q. Ye, and J.P. Powers Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors Bioorg. Med. Chem. Lett. 19 2009 1797 1801
83. D. Sun, Z. Wang, M. Cardozo, R. Choi, M. DeGarffenreid, Y. Di, X. He, J.C. Jen, M. Labelle, J. Liu, J. Ma, S. Miao, A. Sudom, L. Tang, H. Tu, S. Ursu, N. Walker, X. Yan, Q. Ye, J.P. Powers, Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11β- hydroxysteroid dehydrogenase type1, Bioorg. Med. Chem. Lett., 19 (2009) 1522-1527.
84. L. Johansson, C. Fotsch, M.D. Bartberger, V.M. Castro, M. Chen, M. Emery, S. Gustafsson, C. Hale, D. Hickman, E. Homan, S.R. Jordan, R. Komorowski, A. Li, K. McRae, G. Mioniz, G. Matsumoto, C. Oriheuela, G. Palm, M. Veniant, M. Wang, M. Williams, and J. Zhang 2-Amino-1 3-thizaol 4(5H)-ones as potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharrmacodynamic effects in C57B1/6 mice J. Med. Chem. 51 2008 2933 2943 (Pubitemid 351706022)
85. S.P. Webster, M. Binnie, K.M.M. McConnell, K. Sooy, P. Ward, M.F. Greaney, A. Vinter, T.D. Pallin, H.J. Dyke, M.I.A. Gill, I. Warner, J.R. Seckl, and B.R. Walker Modulation of 11β-hydroxysteroid dehydrogenase type 1 activity by 1, 5-substituted 1H-tetrazoles Bioorg. Med. Chem. Lett. 20 2010 3265 3271
86. X. Su, F. Pradaux-Caggiano, M.P. Thomas, M.W.Y. Szeto, H.A. Halem, M.D. Culler, N. Vicker, and B.V.L. Potter Discovery of admantyl ethanone derivatives as potent 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors Chem. Med. Chem. 5 2010 1 20
87. Y.A. Al-Soud, E. Bey, A. Oster, S. Marchais-Oberwinkler, R. Werth, P. Kruchten, M. Forstshcer, and R.W. Hartmann The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1 and type 2 Mol. Cell. Endocrinol. 301 2009 212 215
88. M. Frotscher, E. Ziegler, S. Marchais-Oberwinkler, P. Kruchten, A. Neugebauer, L. Fetzer, C. Scherer, U. Muller-Vieira, J. Messinger, H. Thole, and R.W. Hartmann Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases J. Med. Chem. 51 2008 2158 2169 (Pubitemid 351503271)
89. S. Marchais-Oberwinkler, P. Kruchten, M. Frostcher, E. Ziegler, A. Negebauer, U. Bhoga, E. Bey, U. Muller-Vieria, J. Messinger, H. Thole, and R.W. Hartmann Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1): design, synthesis, biological evaluation and pharmacokinetics J. Med. Chem. 51 2008 4685 4698
90. E. Bey, S. Marchais-Oberwinkler, R. Werth, M. Negri, Y.A. Al-Soud, P. Kruchten, A. Oster, M. Frostcher, B. Birk, and R.W. Hartmann Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl)substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal uinhibitors of 17β-hydroxysteroid dehydrogenaase type 1 (17β-HSD1) J. Med. Chem. 51 2008 6725 6739
91. E. Bey, S. Marchais-Oberwinkler, M. Negri, P. Kruchten, A. Oster, T. Klein, A. Spadaro, R. Werth, M. Frotscher, B. Birk, and R.W. Hartmann New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitory activity and selectivity J. Med. Chem. 52 2009 6724 6743
92. A. Oster, T. Klein, R. Werth, P. Kruchten, E. Bey, M. Negri, S. Marchais-Oberwinkler, M. Frotscher, and R.W. Hartmann Novel estrone mimetics with high 17β-HSD1 inhibitory activity Bioorg. Med. Chem. 18 2010 3494 3505
93. G.M. Allan, N. Vicker, H.R. Lawrence, H.J. Tutill, J.M. Day, M. Huchet, E. Ferrandis, M.J. Reed, A. Purohit, and B.V. Potter Novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1: templates for design Bioorg. Med. Chem. 16 8 2008 4438 4456 (Pubitemid 351545841)
94. B.E. Fink, A.V. Gava, J.S. Tokarski, B. Goyal, R. Misra, H.-Y. Xiao, S.D. Kimball, W.-C. Han, D. Norris, T.E. Spires, D. You, M.M. Gottardis, M.V. Lorenzi, and G.D. Vite Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3 Bioorg. Med. Chem. Lett. 16 2006 1532 1536 (Pubitemid 43197517)
95. N. Vicker, C.M. Sharland, W.B. Heaton, A.M. Gonzalez, H.V. Bailey, A. Smith, J.S. Springall, J.M. Day, H.J. Tutill, M.J. Reed, A. Purohit, and B.V. Potter The design of novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors Mol. Cell. Endocrinol. 301 2009 259 265
96. D. Fournier, D. Poirier, M. Mazumdar, and S.-X. Lin Design and synthesis of bisubstrate inhibitors of type 1 17β-hydroxysteroid dehydrogenase: overview and perspectives Eur. J. Med. Chem. 43 2008 2298 2306
97. M. Mazumdar, D. Fornier, D.-W. Zhu, C. Cadot, D. Poirier, and S.-X. Lin Binary and ternary crystal structure analyses of a novel inhibitor with 17β-HSD type 1: a lead compound for breast cancer therapy Biochem. J. 424 2002 357 366
98. D. Poirier, R.P. Boivin, M.R. Tremblay, M. Berube, W. Qiu, and S.-X. Lin Estradiol-adenosine hybrid compounds designed to inhibit type 1 17β-hydroxysteroid dehydrogenase J. Med. Chem. 48 2005 8134 8147 (Pubitemid 43032522)
99. H.R. Lawrence, N. Vicker, G.M. Allan, A. Smith, M.F. Mahon, H.J. Tutill, A. Purohit, M.J. Reed, and B.V. Potter Novel and potent 17β-hydroxysteroid dehydrogenase type 1 inhibitors J. Med. Chem. 48 8 2005 2759 2762 (Pubitemid 40548090)
100. N. Vicker, H.R. Lawrence, G.M. Allan, C. Bubert, A. Smith, H.J. Tutill, A. Purohit, J.M. Day, M.F. Mahon, M.J. Reed, and B.V. Potter Focused libraries of 16-substituted estrone derivatives and modified-E-ring steroids: inhibitors of 17β-hydroxysteroid dehydrogenase type 1 Chem. Med. Chem. 1 2006 464 481
101. T.M. Penning, R. Thronton, and J.W. Ricigliano Clues to the development of mechanism-based inactivators of 3α-hydroxysteroid dehydrogenase comparison of steroidal and nonsteroidal Michael acceptors and epoxides Steroids 56 1991 420 427
102. R.J. Auchus, and D.F. Covey Mechanism-based inactivation of 17β 20α-hydroxysteroid dehydrogenase by an acetylenic secoestradiol Biochemistry 25 23 1986 7295 7300 (Pubitemid 17220439)
103. B.P. Schlegel, J.E. Pawlowski, Y. Hu, D.M. Scolnick, D.F. Covey, and T.M. Penning Secosteroid mechanism-based inactivators and site-directed mutagenesis as probes for steroid hormone recognition by 3α-hydroxysteroid dehydrogenase Biochemistry 33 34 1994 10367 10374 (Pubitemid 24281802)
104. P.M. Stewart, A.M. Wallace, R. Valentino, D. Burt, C.H. Shackleton, and C.R. Edwards Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age Lancet 2 8563 1987 821 824
105. D. Classen-Houben, D. Schutser, T. Da Cunha, A. Odermatt, G. Wolber, U. Jordis, and B. Kueenburg Selective inhibition of 11β-hydroxysteroid dehydrogenase 1 by 18α-glycyrrhetinic acid but not 18β-glycyrhetinic acid J. Steroid Biochem. Mol. Biol. 113 2009 248 252
106. P. Brozic, S. Turk, T.L. Rizner, and S. Gobec Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening Mol. Cell. Endocrinol. 301 2009 245 250
107. U. Dhagat, V. Carbone, R.P. Chung, T. Matsunaga, S. Endo, A. Hara, and O. El-Kabbani A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20α-hydroxysteroid dehydrogenase Med. Chem. 3 6 2007 546 550 (Pubitemid 350303069)
108. H. Yang, Y. Shen, J. Chen, Q. Jiang, Y. Leng, and J. Shen Structure-based virtual screening for identification of novel 11β-HSD 1 inhibitors Eur. J. Med. Chem. 44 2009 1167 1171
109. D. Schuster, L.C. Nashev, J. Kirchmair, C. Laggner, G. Wolber, T. Langer, and A. Odermatt Discovery of nonsteroidal 17β-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries J. Med. Chem. 2008 2008 4188 4199 (Pubitemid 352032443)
110. J. Hofland, W. van Weerden, N. Dits, J. Steenbergen, G. van Leenders, G. Jenster, F. Schröder, and F. de Jong Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer Cancer Res. 70 2010 1256 1264
111. B. Husen, K. Huhtinen, T. Saloniemi, J. Messinger, H.H. Thole, and M. Poutanen Human hydroxysteroid (17-β) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts Endocrinology 147 11 2006 5333 5339 (Pubitemid 44790588)
112. D.J. Wake, and B.R. Walker 11 β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome Mol. Cell. Endocrinol. 215 2004 45 54 (Pubitemid 38333242)